Fental Matrix 50 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

fental matrix 50 micrograms/hour transdermal patch

rowex ltd - fentanyl - transdermal patch - 50 microgram per hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 50 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 50 micrograms/hour transdermal patch

imbat limited - fentanyl - transdermal patch - 50 micrograms/hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 75 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 75 micrograms/hour transdermal patch

imbat limited - fentanyl - transdermal patch - 75 micrograms/hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 25 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 25 micrograms/hour transdermal patch

imbat limited - fentanyl - transdermal patch - 25 micrograms/hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 100 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 100 micrograms/hour transdermal patch

imbat limited - fentanyl - transdermal patch - 100 micrograms/hour - phenylpiperidine derivatives; fentanyl

FENTANYL patch United States - English - NLM (National Library of Medicine)

fentanyl patch

quality care products, llc - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 1 h - fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use fentanyl transdermal system is contraindicated in: prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.5)] . available data with fentanyl transdermal system in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in animal reproduction studies, fentanyl administration to pregnant rats during organogenesis was

Durogesic DTrans 100 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 100 micrograms/hour transdermal patch

janssen sciences ireland uc - fentanyl - transdermal patch - 100 micrograms/hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 12 micrograms/hour Transdermal Patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 12 micrograms/hour transdermal patch

janssen sciences ireland uc - fentanyl - transdermal patch - 12 micrograms/hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 25 micrograms/hour transdermal patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 25 micrograms/hour transdermal patch

janssen sciences ireland uc - fentanyl - transdermal patch - 25 micrograms/hour - phenylpiperidine derivatives; fentanyl

Durogesic DTrans 50 micrograms/hour Transdermal Patch Ireland - English - HPRA (Health Products Regulatory Authority)

durogesic dtrans 50 micrograms/hour transdermal patch

janssen sciences ireland uc - fentanyl - transdermal patch - 50 micrograms/hour - phenylpiperidine derivatives; fentanyl